NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Get Free Report) has been given an average recommendation of “Moderate Buy” by the twelve analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, nine have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $49.00.
A number of equities research analysts recently weighed in on NAMS shares. Truist Financial assumed coverage on NewAmsterdam Pharma in a research report on Wednesday, March 18th. They set a “buy” rating and a $57.00 target price on the stock. Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Tuesday, April 21st. Finally, Royal Bank Of Canada boosted their price objective on NewAmsterdam Pharma from $47.00 to $51.00 and gave the company an “outperform” rating in a research report on Tuesday, June 30th.
Get Our Latest Research Report on NewAmsterdam Pharma
Insider Transactions at NewAmsterdam Pharma
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the business. Capital World Investors grew its stake in shares of NewAmsterdam Pharma by 17.1% in the 3rd quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock valued at $279,358,000 after purchasing an additional 1,434,986 shares during the period. Handelsbanken Fonder AB lifted its position in shares of NewAmsterdam Pharma by 18.8% during the 3rd quarter. Handelsbanken Fonder AB now owns 405,800 shares of the company’s stock worth $11,541,000 after buying an additional 64,200 shares during the period. Swedbank AB acquired a new stake in NewAmsterdam Pharma in the 4th quarter valued at $3,189,000. American Century Companies Inc. boosted its stake in NewAmsterdam Pharma by 17.1% in the 3rd quarter. American Century Companies Inc. now owns 624,285 shares of the company’s stock valued at $17,755,000 after buying an additional 91,369 shares in the last quarter. Finally, Legato Capital Management LLC grew its position in NewAmsterdam Pharma by 258.7% in the fourth quarter. Legato Capital Management LLC now owns 83,833 shares of the company’s stock valued at $2,941,000 after acquiring an additional 60,463 shares during the period. Institutional investors and hedge funds own 89.89% of the company’s stock.
NewAmsterdam Pharma Price Performance
NAMS opened at $34.83 on Monday. The stock’s 50 day moving average price is $32.93 and its two-hundred day moving average price is $33.08. The firm has a market capitalization of $4.07 billion, a P/E ratio of -19.46 and a beta of 0.08. NewAmsterdam Pharma has a 12-month low of $18.70 and a 12-month high of $42.21.
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last issued its quarterly earnings results on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. The business had revenue of $3.04 million for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%. As a group, analysts anticipate that NewAmsterdam Pharma will post -1.78 earnings per share for the current year.
NewAmsterdam Pharma Company Profile
NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.
The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.
Featured Articles
- Five stocks we like better than NewAmsterdam Pharma
- Visa’s Open USD Push Puts Circle’s Stablecoin Moat Under Pressure
- This Under-the-Radar Industrial Is Quietly Powering AI
- Why Microsoft Looks Like the Best Big Tech Trade for H2 2026
- Strategy’s Bitcoin Pivot Gives Investors a New Reason to Watch Preferred Shares
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
